Sweden · Delayed Price · Currency is SEK Ascelia Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Fiscal Year 2025
-
Lead program Orviglance is in FDA review with a decision expected by July, targeting a significant unmet need in liver imaging for cancer patients with severe renal impairment. Financials show a SEK 16 million Q4 loss and SEK 50 million cash, with partnership discussions and launch preparations progressing well.
-
Orviglance is on track for FDA approval in July 2026, targeting an $800M global market for liver MRI contrast in cancer patients with severe kidney impairment. Q4 saw a SEK 16M operating loss, SEK 15M in liquid assets, and ongoing partnering discussions for commercialization.
-
The company is advancing Orviglance, a gadolinium-free liver MRI agent for patients with severe renal impairment, with FDA approval expected by July 3rd. Extensive clinical data and strong market research support its differentiation and commercial potential, while partner discussions and medical community engagement are ongoing.
-
A novel manganese-based imaging agent for liver cancer is nearing FDA approval, offering a safer alternative to gadolinium for patients with kidney issues. Clinical trials show improved detection of small lesions and a strong safety profile, with commercialization plans underway.
-
NDA for Orviglance submitted, targeting FDA approval for liver MRI in high-risk patients. SEK 30M raised and convertibles converted, extending runway into Q4 next year. Focus remains on securing a commercialization partner and preparing for a U.S. launch.
-
OrbiGlans NDA was submitted to the FDA, with approval expected by July 2026, targeting a $800M market for liver imaging in cancer patients with impaired kidney function. Financials show a SEK 15M Q3 loss, SEK 72M in cash, and a strengthened balance sheet after recent financing.
-
NDA submission for Orviglance is imminent, with strong clinical results and a clear commercialization strategy focused on partnering. Financial position is stable through year-end, supported by recent warrant proceeds and loan repayment.
-
NDA submission for Orviglance is imminent, supported by strong clinical data and robust financials, with SEK 60 million in cash and a clear commercialization strategy focused on partnerships. Oncoral's phase II start depends on securing sufficient partnering funds.
-
Orviglance is advancing toward FDA submission in early August, supported by strong phase 3 data and a recent SEK 43 million warrant exercise, extending the cash runway to year-end. Partnering discussions are ongoing, with a focus on optimizing commercialization and financial sustainability.
-
Orviglance is on track for NDA submission in August 2025, supported by strong phase III data and a robust financial position after a successful warrant exercise. Partnering discussions for commercialization are advancing, with the U.S. prioritized for launch.
-
Orviglance, a manganese-based MRI agent for patients with severe renal disease, is on track for NDA submission mid-year after strong phase III results. Commercialization will be through a partner, targeting a focused U.S. market segment, while industry trends favor safer, non-gadolinium agents.
Fiscal Year 2024
-
Orviglance completed phase III with strong results and is on track for NDA submission mid-2025, targeting a significant unmet need in liver imaging for cancer patients with kidney impairment. Financials show a Q4 loss and a solid cash runway, with commercialization and partnering progressing.
-
Orviglance achieved positive phase III results and is advancing toward NDA submission, supported by a fully subscribed SEK 105M rights issue that extends the cash runway to late 2025. Commercialization and partnering discussions are ongoing, with Oncoral set for phase II in gastric cancer.
-
Strong Phase 3 results for Orviglance set the stage for NDA submission and commercialization, supported by a SEK 105 million rights issue. Q2 saw reduced losses and ongoing partnering discussions, with a focus on regulatory milestones and launch readiness.
-
The presentation highlighted strong phase III results for Orviglance, a novel oral diagnostic for cancer patients with renal disease, with NDA submission targeted for mid-2025. Commercialization efforts focus on the U.S. market, while Oncoral's development will proceed as resources allow.